| P2093 | author name string | Thompson WG | |
| | Camilleri M | |
| | Heading RC | |
| P2860 | cites work | Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice | Q58061440 |
| | Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis | Q22008795 |
| | Idiopathic bile acid catharsis | Q24541382 |
| | Towards positive diagnosis of the irritable bowel | Q24674701 |
| | Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder | Q31837263 |
| | Ischemic colitis during treatment with alosetron | Q31837447 |
| | Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome | Q33422637 |
| | The role of intestinal gas in functional abdominal pain | Q33423659 |
| | Abnormal colonic fermentation in irritable bowel syndrome | Q33487908 |
| | Screening guidelines for colorectal cancer | Q33544268 |
| | Functional somatic syndromes: one or many? | Q33734181 |
| | Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome | Q33751642 |
| | Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans | Q33844909 |
| | Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial | Q33896354 |
| | Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis | Q33923878 |
| | Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials | Q33969643 |
| | Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures | Q34007167 |
| | Treatment of irritable bowel syndrome: a review of randomised controlled trials | Q34130605 |
| | Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns | Q34271456 |
| | Bran and irritable bowel syndrome: time for reappraisal | Q34322516 |
| | U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact | Q34353536 |
| | Ambulatory small intestinal motility in 'diarrhoea' predominant irritable bowel syndrome | Q34377890 |
| | Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea | Q34390051 |
| | Diagnostic value of the Manning criteria in irritable bowel syndrome | Q34391764 |
| | Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects | Q34392063 |
| | More accurate diagnosis of irritable bowel syndrome by the use of 'non-colonic' symptomatology | Q34394237 |
| | Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction | Q34395481 |
| | Colorectal cancer screening: clinical guidelines and rationale | Q34415772 |
| | Psychological significance of the irritable colon syndrome | Q34473501 |
| | What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? | Q34525181 |
| | Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications | Q43437812 |
| | Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome | Q44854221 |
| | Clinical economics review: irritable bowel syndrome. | Q45017501 |
| | 5-HT induces cAMP production in crypt colonocytes at a 5-HT4 receptor | Q45113567 |
| | The impact of irritable bowel syndrome on health-related quality of life | Q46485395 |
| | The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of Agonists | Q46641806 |
| | The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices | Q46728821 |
| | Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells | Q48548051 |
| | Regional cerebral activity in normal and pathological perception of visceral pain | Q48824919 |
| | Irritable bowel syndrome--post salmonella infection | Q50147791 |
| | Rapid gastric emptying in patients with functional diarrhea | Q50157506 |
| | Psychometric scores and persistence of irritable bowel after infectious diarrhoea. | Q51117034 |
| | Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. | Q51119806 |
| | Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. | Q51565061 |
| | Antidepressants for functional gastrointestinal syndromes. | Q52022100 |
| | Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders | Q52860277 |
| | Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. | Q53348988 |
| | Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. | Q53524367 |
| | Patient‐perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life | Q53595907 |
| | Altered rectal perception is a biological marker of patients with irritable bowel syndrome. | Q53641269 |
| | Role of loperamide and placebo in management of irritable bowel syndrome (IBS) | Q55062522 |
| | Microsatellite instability | Q57742296 |
| | Irritable Bowel Syndrome–Prognosis and Diagnostic Safety | Q57806938 |
| | Irritable bowel-type symptoms in spontaneous and induced constipation | Q34527848 |
| | Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study | Q34527904 |
| | 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit | Q34528298 |
| | Bladder smooth muscle dysfunction in patients with irritable bowel syndrome | Q34530654 |
| | Food intolerance and the irritable bowel syndrome | Q34532110 |
| | Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients | Q34738753 |
| | Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis | Q34749614 |
| | Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. | Q34754851 |
| | Level of chronic life stress predicts clinical outcome in irritable bowel syndrome | Q35351736 |
| | The role of psychological and biological factors in postinfective gut dysfunction | Q35354188 |
| | Validation of a specific quality of life questionnaire for functional digestive disorders | Q35354662 |
| | Irritable bowel syndrome in general practice: prevalence, characteristics, and referral | Q35358389 |
| | Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome | Q35362266 |
| | Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians, and The Association of Coloproctology of Great Britain and Ireland | Q35557583 |
| | The irritable bowel syndrome: mechanisms and a practical approach to management | Q36110388 |
| | Differences between males and females in rates of serotonin synthesis in human brain | Q36772213 |
| | Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study | Q37417328 |
| | Irritable bowel syndrome and psychiatric illness | Q37916056 |
| | Intergenerational transmission of gastrointestinal illness behavior | Q38497746 |
| | Motility disorders and stress | Q38723217 |
| | Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study | Q38961749 |
| | Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome | Q39432760 |
| | Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients | Q39434734 |
| | Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea | Q39436086 |
| | Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist | Q39436676 |
| | Sexual and physical abuse and gastrointestinal illness. Review and recommendations | Q40421797 |
| | Diagnosing and treating patients with refractory functional gastrointestinal disorders | Q40421813 |
| | Fluoxetine | Q40637345 |
| | The irritable bowel syndrome: long-term prognosis and the physician-patient interaction | Q40650690 |
| | Clinical management of intractable constipation | Q40692986 |
| | Irritable colon and depression | Q40948743 |
| | The epidemiology of irritable bowel syndrome in a random population: prevalence, incidence, natural history and risk factors | Q41027346 |
| | Gender variations in clinical pain experience | Q41127139 |
| | Review article: irritable bowel syndrome | Q41356171 |
| | Irritable bowel syndrome: a technical review for practice guideline development | Q41493711 |
| | Irritable bowel syndrome. Diagnosis in the managed care era. | Q41513369 |
| | Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients | Q41714645 |
| | Bile duct ligation in rats induces biliary expression of cytokine-induced neutrophil chemoattractant | Q41738693 |
| | Irritable bowel syndrome in office-based practice in the United States | Q41878297 |
| | Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers | Q42048821 |
| | Effect of bile acid perfusion on colonic motor function in patients with the irritable colon syndrome | Q42218637 |
| | Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome | Q43250132 |
| | Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization | Q43326887 |
| | Irritable bowel syndrome defined by factor analysis. Gender and race comparisons | Q43329436 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irritable bowel syndrome | Q838966 |
| P304 | page(s) | 1407-1430 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome | |
| P478 | volume | 16 | |